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The yeast CDC9 gene encodes both a nuclear and a
mitochondrial form of DNA ligase I
M. Willer, M. Rainey, T. Pullen and C.J. Stirling
Background: The yeast CDC9 gene encodes a DNA ligase I activity required
during nuclear DNA replication to ligate the Okazaki fragments formed when
the lagging DNA strand is synthesised. The only other DNA ligase predicted
from the yeast genome sequence, DNL4/LIG4, is specifically involved in a
non-homologous DNA end-joining reaction. What then is the source of the DNA
ligase activity required for replication of the yeast mitochondrial genome?
Results: We report that CDC9 encodes two distinct polypeptides expressed
from consecutive in-frame AUG codons. Translational initiation at these two
sites gives rise to polypeptides differing by a 23 residue amino-terminal
extension, which corresponds to a functional mitochondrial pre-sequence
sufficient to direct import into yeast mitochondria. Initiation at the first AUG
codon results in a 755 amino-acid polypeptide that is imported into
mitochondria, whereupon the pre-sequence is proteolytically removed to yield
the mature mitochondrial form of Cdc9p. Initiation at the second AUG codon
produces a 732 amino-acid polypeptide, which is localised to the nucleus. Cells
expressing only the nuclear isoform were found to be specifically defective in
the maintenance of the mitochondrial genome.
Conclusions: CDC9 encodes two distinct forms of DNA ligase I. The first is
targeted to the mitochondrion and is required for propagation and maintenance
of mitochondrial DNA, the second localises to the nucleus and is sufficient for
the essential cell-division function associated with this gene.
Background
DNA ligases have important roles in several aspects of
DNA metabolism including replication, recombination
and repair. In mammalian nuclear extracts, four different
classes of ligase have been identified. DNA ligase I func-
tions in the ligation of Okazaki fragments, which are
formed when the lagging strand of DNA is synthesised
during replication [1,2], and has been further implicated in
DNA repair [3]. DNA ligase III interacts with the XRCC1
protein, which is known to be involved in both recombina-
tion and repair, thus implicating DNA ligase III in these
processes [4,5]. A testis-specific splice variant of DNA
ligase III has also been identified, which does not interact
with XRCC1 and whose specific role is currently unknown
[6]. DNA ligase II is smaller than DNA ligase III but the
degree of structural similarity between the two has led to
the suggestion that DNA ligase II might correspond to
either a splice variant or a proteolytic derivative of DNA
ligase III [7,8]. Finally, DNA ligase IV has a different sub-
strate specificity from DNA ligases I and III and is essen-
tial in mice, but its biological role has not yet been defined
[9,10]. In Saccharomyces cerevisiae, the CDC9 gene encodes a
DNA ligase I that is essential for completion of DNA syn-
thesis [11]. Conditional lethal cdc9 mutant cells are defec-
tive in ligation of Okazaki fragments, are hypersensitive to
DNA-damaging agents, and show enhanced frequency of
mitotic recombination. Consistent with its role in DNA
replication, the expression of CDC9 has been shown to be
cell cycle regulated in exponentially growing cells with its
transcript level reaching a maximum at the G1–S boundary
[12,13]. Nevertheless, expression of CDC9 can also be
induced in stationary-phase cells upon exposure to
DNA-damaging agents, thereby satisfying the require-
ment for Cdc9p in DNA repair [11,14]. 
A second DNA ligase with DNA end-joining activity has
been identified in yeast cell extracts [15] and seems likely
to correspond to the product of an open reading frame
(ORF) designated YOR005c, identified in the yeast
genome as a homologue of mammalian DNA ligase IV. In
three independent studies using reverse genetic analysis
[16–18], it has been demonstrated that YOR005c does
indeed encode a ligase activity; the ORF has been
renamed DNL4 [18] and LIG4 [16,17]. The DNL4/LIG4
gene predicts a 109 kDa polypeptide product that shares
25% sequence identity with mammalian DNA ligase IV
but only 21% identity with yeast Cdc9p. Unlike CDC9, the
DNL4/LIG4 gene is not essential for growth; indeed null
mutant cells exhibit no obvious defects in either DNA
replication or excision-repair [16–18]. Nevertheless,
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dnl4/lig4 mutant cells have been shown to sustain a sub-
stantially reduced level of non-homologous DNA end-
joining, suggesting a role for Dnl4p/Lig4p in this process
in vivo [16,18]. 
Given its role in nuclear DNA replication, it is not surpris-
ing that the mammalian DNA ligase I has been shown to
be located in the nucleus [19]. The absence of any further
ligase homologues in the yeast genome, however, raises an
important question as to the source of DNA-ligase activity
that would be required for the replication of the mitochon-
drial genome. The yeast mitochondrial genome is an
85.78 kb covalently closed circle encoding a small number
of mitochondrial proteins, none of which show any similar-
ity to known ligases. As CDC9 encodes the only replica-
tion-specific ligase currently known in yeast, we undertook
a detailed analysis of the expression and intracellular local-
isation of the CDC9 gene product. We report that CDC9
encodes two distinct polypeptide products that are trans-
lated from separate in-frame initiation codons. The longer
form is targeted to the mitochondrion where it is required
for mitochondrial DNA replication. The shorter polypep-
tide product is targeted to the nucleus and is essential for
nuclear DNA replication and cell viability.
Results
Expression and localisation of Cdc9–GFP fusion proteins
Previous studies have shown that transcription of CDC9
initiates 39–41 bp upstream of the first AUG codon
(AUG1) in the ORF [11,14]. Translation initiation at AUG1
would yield a 755 amino-acid polypeptide with a predicted
molecular weight of 84.8 kDa [11]. Analysis of the CDC9
sequence, however, revealed several further in-frame
methionine codons including AUG2, AUG3 and AUG4
located at codons +24, +48 and +66, respectively
(Figure 1a). To determine which, if any, of these four
potential start codons might initiate translation of Cdc9p in
vivo, a series of GFP fusion proteins were generated and
the products detected by western blotting with anti-GFP
antibodies (Figure 2). Cells transformed with a vector
expressing GFP alone (pUG23) contained a single
immunoreactive band of the expected relative molecular
weight of 26.8 kDa. Cells carrying a plasmid in which GFP
was fused after AUG3 (pMW182) contained three
immunoreactive species of 34.1, 31.5 and 29.0 kDa, consis-
tent with initiation at AUG1, AUG2 and AUG3, respec-
tively (Figure 2b). Similarly, three distinct species were
observed when GFP was fused after codon 70 downstream
of AUG4 (in plasmid pMW181). The relative molecular
weights of these three species (35.4, 32.8, 30.3 kDa) were
again consistent with initiation at each of the first three
AUG codons. No species was detected with the mobility
expected from initiation at the fourth AUG. 
We noted that residues 1–23 of Cdc9p could form an
amphipathic α helix with properties similar to those com-
monly found in mitochondrial pre-sequences (see
Figure 1b) [20]. Should this constitute a functional pre-
sequence, then full-length Cdc9p might be predicted to
be targeted to the mitochondrial matrix where the pre-
sequence might be removed by mitochondrial pre-
sequence peptidase (MPP) [21]. Indeed, a consensus
cleavage site for MPP cleavage exists in the sequence
ARFFT (in the single-letter amino-acid code; amino-acid
residues 42–46), predicting cleavage between residues F44
and F45 (Figure 1a; [22]). Such a cleavage product would
be very similar in molecular weight to any bona fide transla-
tion product initiated from the nearby AUG3. To distin-
guish these possibilities, we mutated both the AUG2 and
AUG3 codons in the AUG1–4 construct to GCG (Ala) and
then examined the expression profile in vivo
(AUG1,4–GFP; Figure 2b). Cells carrying this construct
(pMW197) were found to express two major bands with
gel mobilities indistinguishable from the 35.4 and
30.3 kDa forms observed with the wild-type AUG1–4-GFP
construct; the 32.8 kDa form predicted to initiate at AUG2
was lacking, however (Figure 2b; lanes 3,4). The presence
of the 30.3 kDa form in pMW197-containing cells 
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Figure 1
Structure of the CDC9 ORF. (a) Predicted
protein sequence. Asterisks, the four amino-
terminal methionine codons (AUG1–4);
arrow, consensus site for possible cleavage
by the MPP [22] (the location of the
cleavage site between residues 44 and 45
suggests that the first 44 amino-terminal
residues (boxed) might represent a
mitochondrial pre-sequence); underlined
sequences, nuclear localisation signals [22];
inverted black triangle, position of the triple
HA epitope tag inserted in strain MDY26
(see Materials and methods).
(b) Alpha-helical wheel of the first 18
residues (shown in single-letter amino acid
code) of the predicted Cdc9 protein reveals
an amphipathic structure characteristic of
mitochondrial targeting sequences [20].
Black circles, hydrophobic residues; +,
positively charged residues.
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indicates that it cannot be a product of initiation at AUG3,
but rather suggests that it must be a proteolytic product of
the full-length polypeptide expressed from AUG1. If this
processing was by MPP, then the 30.3 kDa form would be
expected to fractionate with mitochondria. Therefore,
purified mitochondria and a cytosolic fraction were pre-
pared from cells carrying the AUG1–3-GFP fusion con-
struct (pMW182) and analysed by western blotting
(Figure 2c). The 34.1 and 29.0 kDa forms were found to
cofractionate with purified mitochondria, whereas the
31.5 kDa form was exclusively located in the cytosolic frac-
tion. The small proportion of 29.0 kDa species present in
the cytosol might have been released from broken mito-
chondria or might reflect very limited translational initia-
tion from AUG3. 
To confirm that cofractionation of Cdc9–GFP with purified
mitochondria reflects authentic localisation to this compart-
ment, we next examined the patterns of GFP fluorescence
in intact cells. Cells carrying pMW181 (AUG1–4–GFP) were
first compared, using conventional fluorescence
microscopy, with those expressing GFP alone (pUG23).
Cells carrying the GFP vector exhibited a strong gener-
alised background staining consistent with a predominantly
cytoplasmic localisation. In contrast, cells expressing
Cdc9–GFP exhibited a strong pattern of green fluores-
cence localised to tubular and punctate structures, with a
weak general background fluorescence (see Supplementary
material published with this article on the internet).
Control cells lacking GFP exhibited no fluorescence signal
(data not shown). There was considerable correspondence
between the tubular/punctate staining observed with
Cdc9–GFP and extranuclear 4,6-diamidino-2-phenylindole
(DAPI) staining of mitochondrial DNA, consistent with a
mitochondrial localisation for Cdc9–GFP (see Supplemen-
tary material). This was confirmed by colocalisation of
Cdc9–GFP with the mitochondrial heat-shock protein
Hsp60, observed by confocal immunofluorescence
microscopy (Figure 3a,b). The Hsp60 staining was strik-
ingly similar to the pattern of Cdc9–GFP fluorescence
observed in these cells (Figure 3a). Indeed, a merged
image of Hsp60 and Cdc9–GFP staining in a dividing cell
showed precise colocalisation of the two signals
(Figure 3b). These data clearly indicate that the amino-ter-
minal region of Cdc9p does indeed contain a functional
mitochondrial pre-sequence. Moreover, the data indicate
that both AUG1 and AUG2 in yeast CDC9 can initiate trans-
lation of a GFP fusion protein in vivo, and suggest that the
longer translation product is targeted to the mitochondrion
where it is processed by MPP.
Epitope tagging of full-length Cdc9
To detect the yeast CDC9 gene product, we first 
introduced a triple HA tag using the transposon inser-
tion/excision method developed by Ross-MacDonald
et al. ([23]; Cdc9–HA). Several insertions were obtained
that did not interfere with the normal growth rates of
haploid strains, indicating that these tagged alleles
retained full Cdc9 activity. Western blot analysis
revealed that, in all cases, these cells contained a doublet
of immunoreactive bands with relative gel mobilities of
approximately 90–93 kDa. This is marginally smaller
than the 94.9 kDa predicted from the sequence of the
epitope-tagged Cdc9–HA. The results for one such inser-
tion are shown in Figure 4a; this particular strain
(MDY26) was used in the remaining experiments. 
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Figure 2
Cdc9–GFP constructs are translated from
multiple start codons and proteolytically
processed in mitochondria. (a) The 5′ end of
the CDC9 ORF is shown schematically with
the positions of AUG1–4 indicated to scale.
The structure of potential GFP fusion proteins
expressed from AUG1–3 in pMW182 and
AUG1–4 in pMW181 are shown, together with
their predicted molecular weights. M, initiating
methionine residue; grey box, GFP; arrow,
putative site of mitochondrial pre-sequence
processing. The AUG2 and AUG3 codons in
pMW182 were both mutated to GCG to
produce pMW197 (AUG1,4) as described in
the Materials and methods section.
(b) Western blot of total cell extracts from
yeast expressing Cdc9–GFP constructs,
probed with anti-GFP antibody. Lane 1,
pUG23 (no insert); lane 2, pMW182
(AUG1–3); lane 3, pMW181 (AUG1–4); lane 4,
pMW197 (AUG1,4). (c) Subcellular
fractionation of yeast expressing the
Cdc9–GFP fusion proteins encoded by
pMW182 (AUG1–3). Lane 1, total extract;
lane 2, mitochondrial fraction; lane 3,
post-mitochondrial supernatant.
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Intracellular distribution of Cdc9–HA
Next, we determined the localisation of the functional
Cdc9–HA protein by sub-cellular fractionation. Mitochon-
dria were purified by differential centrifugation as
described [24]. The mitochondrial fraction was shown to
be devoid of nuclear contamination by western blotting
with antibodies against several nuclear proteins including
Npl3 (Figure 4b), Swi3 and histone H3 (data not shown).
As expected, the mitochondrial fraction was found to be
enriched for a variety of mitochondrial proteins examined,
namely Hsp60 (Figure 4b), Mdh1 and Porin (data not
shown). Western blotting with anti-HA antibodies
revealed that the mitochondrial fraction contained signifi-
cant levels of Cdc9–HA (Figure 4b).
Enriched nuclear preparations were resolved by sucrose
step-gradient centrifugation. As previously reported [25],
we found that intact nuclei, observed microscopically, were
present at the interface between 1.5–1.8 M sucrose, corre-
sponding to a peak of Npl3 protein detected by western
blotting (Figure 4b, lanes 9–11). A substantial amount of
Npl3 was also detected at the top of the gradient
(Figure 4b, lanes 2–3). This might reflect a cytosolic pool
of Npl3, but might be largely due to a combination of
nuclear breakage and the leakage of proteins through
nuclear pores during the fractionation procedure. The dis-
tribution of other nuclear markers tested, Swi3 and histone
H3, were identical to that of Npl3 (data not shown). As
expected, there was a distinct peak of Cdc9–HA that pre-
cisely coincided with the peak of intact nuclei (Figure 4b,
lanes 9–11), indicating that a proportion  of Cdc9–HA is
localised to the nucleus. The fractions containing intact
nuclei showed marginal contamination with mitochondrial
Hsp60, which was predominantly located towards the top
of this gradient (Figure 4b, lanes 2–3). Identical staining
profiles were also seen with other mitochondrial markers
Mdh1 and Porin (data not shown). 
The nuclear and mitochondrial forms of Cdc9–HA exhibit
different properties
Copurification of Cdc9–HA with mitochondria is consis-
tent with the localisation observed for Cdc9–GFP. To
confirm that Cdc9–HA is imported into mitochondria, as
opposed to being associated with the outer surface of the
organelle, we performed protease-protection studies. Puri-
fied nuclei and mitochondria were separately incubated
with proteinase K in the presence or absence of the deter-
gent Triton X-100. Following incubation, extracts were
analysed by western blotting with anti-HA antibody to
detect any undigested Cdc9–HA protein. The mitochon-
drion-associated form of Cdc9–HA was found to be pro-
tected from proteolysis in the absence of detergent but
was completely sensitive to proteinase K digestion when
incubations were performed in the presence of detergent
(Figure 5a). Identical results were obtained for the mito-
chondrial matrix protein Hsp60 (Figure 5b). As a control,
the purified mitochondria were shown to be devoid of
contamination with a nuclear marker (Figure 5c). These
results indicate that the mitochondrion-associated form of
Cdc9–HA is entirely sequestered within a membrane-
bound compartment. 
The protease accessibility of nucleus-associated
Cdc9–HA was found to be very different. In this case,
Cdc9–HA remained stable during mock incubations in
the absence of protease, but was digested upon incuba-
tion with protease either in the presence or absence of
detergent (Figure 5d). Identical results were obtained for
Npl3 (Figure 5f), consistent with free diffusion of small
proteins such as proteinase K into the nuclear compart-
ment through nuclear pores. As discussed previously, we
found minor contamination of the nuclear fraction with
mitochondrial Hsp60 and, once again, we found that this
was protected from proteolysis in the absence of deter-
gent (Figure 5e). These results indicate that the nucleus-
associated and mitochondrion-associated forms of
Cdc9-HA are topologically distinct. Moreover, we have
noted that the two forms of Cdc9–HA exhibit different
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Figure 3
Cdc9–GFP localises to mitochondria in yeast. (a) Confocal
immunofluorescence microscopy of cells carrying pMW181. The
Cdc9–GFP signal shows a similar distribution to the staining found
with indirect immunofluorescence after incubation with anti-Hsp60
antisera followed by a Cy3 (indocarbocyanine)-conjugated secondary
antibody. Cells were fixed and stained as described in the Materials
and methods section. The images shown correspond to an integration
of 25 separate confocal sections recorded in either the GFP or Cy3
channels. (b) Enlarged area from (a) demonstrating precise overlap
between the mitochondrial Hsp60 and Cdc9–GFP signals.
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gel mobilities. The nuclear form migrated more slowly in
SDS–PAGE than did the mitochondrial form and these
two distinct species corresponded closely to the bands of
the Cdc9–HA doublet observed in the total cell extract
(Figure 6). Taken together, these data indicate the pres-
ence of two distinct forms of Cdc9–HA expressed in
MDY26 cells. The larger form is localised in the nuclear
compartment, whereas the smaller form is localised in
mitochondria. The difference observed in relative molec-
ular weights would be consistent with the nuclear form
being the primary translation product initiated from
AUG2, the mitochondrial form being initiated at AUG1,
and the pre-sequence processed as predicted between
residues 44 and 45. 
AUG1 of CDC9 is required for the maintenance of the
mitochondrial genome
Yeast cells require mitochondria for growth, but the mito-
chondrial genome itself is dispensable. Nevertheless,
mutants lacking some or all of the mitochondrial genome
lack enzymes required for respiratory growth. Such
mutants (‘petite’ mutants) are therefore unable to grow on
non-fermentable carbon sources such as glycerol. If the
mitochondrial and nuclear forms of Cdc9 are expressed
from AUG1 and AUG2, respectively, then a mutation in
AUG1 might be predicted to disrupt the replication of the
mitochondrial genome without impacting on the essential
nuclear function of DNA ligase. To test this hypothesis,
both AUG1 and AUG2 were individually mutated and the
effects on functional expression of CDC9–HA determined.
AUG1 was mutated to a UAG stop codon, and AUG2 to
GCG (Ala). The individual mutations were integrated
into a diploid strain, and the heterozygous diploids dis-
sected and grown on glucose. In either case, viable hap-
loids were recovered carrying the mutant cdc9 allele. A
haploid strain carrying the AUG1→UAG mutation grew
well on glucose medium but was unable to grow on glyc-
erol, demonstrating that these cells were petite (Figure 7).
This compares with otherwise isogenic wild-type and
AUG2→GCG strains, which grew normally on glycerol
(Figure 7). 
Western blot analysis clearly demonstrated that the upper
form of the Cdc9p doublet was absent in AUG2→GCG
mutant cells, whereas the lower form of the doublet was
lacking in the AUG1→UAG mutant, thus confirming that
these forms are indeed expressed from different AUG
codons (data not shown). As CDC9 is an essential gene,
we were initially surprised by the finding that
AUG2→GCG cells were viable. This anomaly would be
most easily explained if, in the absence of AUG2, a scan-
ning ribosome were to now initiate at AUG3 to yield a
functional nuclear form of Cdc9p. Western blot analysis
of the AUG2→GCG mutant strain suggested that this was
indeed the case (data not shown). From these data, we
conclude that the mitochondrial form of Cdc9p is
required for the stable maintenance of mitochondrial
DNA but not for cell division. 
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Expression of Cdc9–HA in yeast. (a) Western blot with anti-HA
antibodies on total extracts prepared from a wild-type haploid yeast
strain (W303-3c, lane 1) and from the MDY26 strain (see Figure 1a)
in which sequences encoding the triple HA tag have been inserted
into the CDC9 gene (lane 2). MDY26 cells express an
immunoreactive doublet of apparent molecular weights 90 and
93 kDa; these are only very marginally smaller than the size predicted
for full-length Cdc9–HA (94.9 kDa). (b) Cdc9–HA is found in both
nuclear and mitochondrial fractions. Intact nuclei were prepared from
MDY26 and purified by centrifugation on a sucrose step-gradient as
described in Materials and methods. Equal volumes of 20 individual
fractions (lanes 1–20) were subjected to western blotting with
antibodies specific to Npl3, HA, or Hsp60. Mitochondria (mito) were
purified from the same cells (see the Materials and methods section)
and equivalent amounts of these were then analysed by western
blotting using the same three antibodies.
Discussion
Mitochondrial DNA replication ought to require an activ-
ity similar to DNA ligase I for the ligation of Okazaki frag-
ments. Analysis of the coding sequence of the yeast CDC9
gene led us to speculate that this gene might encode both
a nuclear and a mitochondrial form of DNA ligase I. The
ORF has several in-frame AUG codons towards its 5′ end
as originally noted by Barker et al. ([11]; see Figure 1).
Translation from AUG1 would lead to a 755 amino-acid
primary translation product of which the amino-terminal
region has several properties characteristic of a mitochon-
drial pre-sequence, most notably, a putative amphipathic
α-helical region (residues 1–18) with a positively charged
face, a general lack of acidic residues and a preponderance
of hydroxylated residues. Moreover, this putative matrix-
targeting signal is followed, between residues 44 and 45,
by a potential site for specific cleavage by the MPP
located within the mitochondrial matrix [20,22]. 
Cleavage at this site would predict a mature mitochondrial
form with a molecular weight of 80.1 kDa, compared with
a predicted primary translation product of 84.8 kDa. Initia-
tion of translation solely at the AUG1 codon would endow
every Cdc9 molecule with this putative pre-sequence.
Any model for Cdc9 expression would have to account,
therefore, for the required expression of a nuclear form of
this enzyme. Translational initiation at AUG2 would
accommodate this as it would result in a 732 amino-acid
primary translation product (82.3 kDa) lacking the amphi-
pathic region discussed above, but which would still
contain the three putative nuclear localisation signals indi-
cated in Figure 1a. This model therefore predicts two
forms of Cdc9p in wild-type yeast cells and, indeed,
Tomkinson et al. [26] reported the purification of wild-
type Cdc9p as a tight doublet of approximately 80 kDa
with an additional 70 kDa proteolytic fragment corre-
sponding to an enzymatically active carboxy-terminal
portion of Cdc9p. 
To test this model, we first engineered several CDC9–GFP
gene fusions and, by western blot analysis, determined the
nature of the fusion proteins expressed in vivo. When
GFP was fused downstream of either AUG3 or AUG4,
translation products were observed in both cases with rela-
tive molecular weights very closely comparable to those
expected from initiation at both AUG1 and AUG2. In addi-
tion, each construct led to the expression of a third major
form whose mobility would be consistent either with initi-
ation at AUG3 or with a mitochondrial processing product
(Figure 2). When the products from AUG1–4–GFP were
compared with those of a mutant derivative in which both
AUG2 and AUG3 were replaced, then a clearer picture
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Figure 6
Two distinct forms of Cdc9–HA are found in nuclei and mitochondria.
Western blot analysis of total cell extract, and mitochondrial and
nuclear preparations from MDY26 probed with antibodies against HA,
Hsp60 and Npl3.
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Figure 5
Cdc9–HA is protected against proteinase K in mitochondrial fractions.
Nuclei and mitochondria were purified from MDY26 and treated with
proteinase K in the absence or presence of Triton X-100 as indicated.
After precipitation with tricarboxylic acid (TCA), the samples were
analysed by western blotting with anti-HA, anti-Hsp60 and anti-Npl3
antibodies. Both (a–c) mitochondria and (d–f) nuclei were subjected
to the four different combinations of proteinase K and/or detergent.
Hsp60
Npl3
Cdc9–HA
(a)
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(d)
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(f)
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emerged. Firstly, the 32.8 kDa product predicted to arise
from initiation at AUG2 was now absent, whereas the
smaller form remained unaffected (Figure 2b). From this,
it is clear that this smaller fusion protein cannot arise
through initiation at AUG3. Fractionation studies of the
three products expressed from  AUG1–3–GFP revealed
that the intermediate species (the size of which was con-
sistent with initiation at AUG2) remained in the soluble
cytosolic phase whereas the other two forms fractionated
with mitochondria. 
These results would be consistent with translational initia-
tion of Cdc9–GFP at both AUG1 and AUG2. The fusion
protein observed with an intermediate gel mobility would
correspond to the product of initiation at AUG2. The
largest species would correspond to the primary translation
product from AUG1, with the smallest form being derived
from this by removal of the pre-sequence on import into
mitochondria. Our fractionation studies indicated that
both the largest and smallest forms of Cdc9–GFP were
mitochondrially associated. It is not clear why a small pro-
portion of the fusion should remain unprocessed although
it may be due to some overexpression from the multicopy
plasmid constructs. The cofractionation of Cdc9–GFP
with mitochondria was confirmed by confocal microscopy
in intact cells where it was found that the majority of the
Cdc9–GFP signal was precisely colocalised with the mito-
chondrial marker, Hsp60 (Figure 3). These results indi-
cate that Cdc9–GFP can be expressed from each of two
consecutive AUG codons corresponding to AUG1 and
AUG2 of CDC9, and that the first of these incorporates a
functional mitochondrial pre-sequence which is cleaved
upon import into mitochondria.
We went on to examine the cellular distribution of an HA-
tagged derivative of Cdc9p. The tagged CDC9–HA gene
expressed functional ligase activity as it could support
wild-type growth rates in a haploid strain background.
Moreover, the tagged Cdc9–HA protein migrated as a
doublet in SDS–PAGE as did native Cdc9p (Figure 4a;
[26]). Nuclei and mitochondria were purified from cells
expressing Cdc9–HA, and western blotting studies
revealed substantial levels of Cdc9–HA in both organelles
(Figure 4b). These two pools of Cdc9–HA were further
distinguished by their protease accessibility in which it
was evident that the mitochondrion-associated form was
entirely sequestered within a sealed membrane-bound
compartment. In contrast, the nuclear form remained char-
acteristically accessible to protease (Figure 5). Moreover,
the two forms could be resolved by SDS–PAGE and their
different mobilities would appear to account for the
Cdc9–HA doublet observed in whole cell extracts
(Figure 6), the higher molecular weight band of the
doublet apparently corresponding to the nuclear form and
the faster-migrating species being indistinguishable from
the mitochondrial form. Overall, these data indicate that
yeast Cdc9 is expressed in two topologically distinct iso-
forms from adjacent AUG codons in the CDC9 ORF. 
The biological significance of these observations was con-
firmed by our findings of the phenotypes of AUG mutants
engineered into the otherwise wild-type CDC9 gene. A
mutant lacking AUG1 remained viable but became petite
(Figure 7). From this, it is evident that initiation at AUG1
is required to produce the DNA ligase necessary to main-
tain mitochondrial DNA, but is not required for replica-
tion of the nuclear genome. Our data further demonstrate
that the nuclear form of Cdc9p is normally expressed from
AUG2, but that initiation at this codon is not essential for
viability because of the close proximity of AUG3, only 24
codons downstream. In the absence of AUG2, a functional
form of Cdc9p is initiated at AUG3. 
The expression of two distinct isoforms of DNA ligase I
might not be restricted to S. cerevisiae. We have found
strong candidates for amino-terminal mitochondrial pre-
sequences encoded by both the Schizosaccharomyces pombe
cdc17 gene [27] and a DNA ligase I homologue from Ara-
bidopsis thaliana [28]. In each case, the putative pre-
sequence is closely followed by a second in-frame AUG
codon. Interestingly, the sequence of the cloned human
DNA ligase I cDNA does not encode any recognisable
mitochondrial pre-sequence. There could of course be
some cryptic mitochondrial import signal, or perhaps an
alternatively spliced mRNA that might incorporate a mito-
chondrial pre-sequence. Alternatively, a second DNA
ligase I homologue in the human genome might encode a
mitochondrial form of this enzyme. Intriguingly, expres-
sion of the human cDNA complements the growth defect
in a yeast cdc9-1 mutant [29]. It would be very interesting
to examine the respiratory competence of such cells to test
for the human enzyme’s ability to complement any mito-
chondrial defect. Interestingly, a DNA ligase III activity
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Figure 7
Functional distinction between Cdc9 encoded from AUG1 and AUG2.
After tetrad analysis, haploid leucine auxotrophs were tested for
growth on YPD (glucose) and YPEG (glycerol) media. The yeast
strains were MWY21 (wild type), MWY32 and MWY51 (heterozygous
diploids in which one copy of CDC9 was engineered to alter either
AUG1 or AUG2, respectively). The specific mutations were
AUG1→UAG and AUG2→GCG. 
GCG
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has been identified in mitochondrial extracts from Xenopus
laevis [30]. More recently, it has been shown that human
DNA ligase III is expressed in both nuclear and mitochon-
drial forms from tandem AUG codons [31] in a manner
which appears similar to that described here for yeast
CDC9. DNA ligase III has been implicated primarily in
DNA repair and recombination but might also perform the
replication role required in the human mitochondrion.
Although antisense inhibition studies indicate that DNA
ligase III is the major source of ligase activity in the
human mitochondrion, they do not, however, exclude the
possibility that other forms of DNA ligase may also func-
tion in this compartment [31]. 
In eukaryotes, the majority of proteins studied have been
shown to be accurately and efficiently sorted to a single
cellular compartment. Nevertheless, several examples are
now known where an enzyme can be expressed in two or
more isoforms from a single genetic locus (for a review, see
[32]). These isoforms can carry distinct targeting signals
leading to their being sorted to different compartments. A
variety of mechanisms can account for the expression of
distinct isoforms but, in yeast, the majority of cases rely on
either altered transcriptional or translational initiation to
produce isoforms which differ at their amino termini (see
[32] and references therein). From our current data, we
cannot determine whether the mechanism responsible for
expression of distinct isoforms of Cdc9p operates at the
transcriptional or the translational level. Previous studies
have reported a single transcriptional initiation site
upstream of the first AUG codon of CDC9 [11,14]. It would
therefore follow that some post-transcriptional mechanism
must serve to ensure the expression of the nuclear form of
yeast DNA ligase I. The nature of this control mechanism
is currently under investigation.
Materials and methods
Strains and culture conditions
All yeast strains used in this study are derived from W303
(MATa/MATα ura3-1/ura3-1 leu2-3,112/leu2-3,112 trp1-1/trp1-1
his3-11/his3-11 ade2-1/ade2-1 can1-100/can1-100) including the
haploid wild-type derivative W303-3c (MATa, ura3-1-1 leu2-3,112
trp1-1-1 his3-11 ade2-1 can1-100), MDY26 (as W303-3c but
CDC9–HA), MWY21 (as W303 but CDC9/cdc9–HA::pMW185),
MWY32 (as W303 but CDC9/cdc9–HA::pMW186), and MWY51 (as
W303 but CDC9/cdc9–HA::pMW190). Yeast cultures were grown in
either YPD (2% peptone, 1% yeast extract, 2% glucose) or, to maintain
selection in YNB (0.675% yeast nitrogen base, 2% glucose), supple-
mented with appropriate amino-acid supplements. Mitochondrial func-
tion was assessed by plating cells on YPEG (2% peptone, 1% yeast
extract, 3% glycerol, 3% ethanol). Sporulation and tetrad dissection
were performed as described previously [33].
Generation of CDC9–GFP fusions
Expression vector pUG23 for carboxy-terminal GFP fusions was kindly
provided by J.H. Hegemann. Two plasmids containing various lengths
of the amino terminus of CDC9 fused in frame to GFP under the
control of a MET25 promoter were constructed. CDC9 was amplified
by PCR with primers A (5′-CATCTAGAACATGCGCAGATTACTG-3′)
and B (5′-GGAGATCTAGTGAATTCTGTTGGCTTATTTTTC-3′) and
subcloned into the EcoRV site of pBluescript KS+ (pMW178);
pMW178 was subsequently digested with XbaI and EcoRI and the
172 bp CDC9 fragment was cloned into the XbaI–EcoRI sites of
pUG23. The resulting plasmid (pMW182) contains GFP fused in frame
after residue 54 of CDC9. A similar construct (pMW181) was made by
cloning a 223 bp XbaI–BamHI fragment of the PCR product with
primers A and C (5′-CTATCGATATGCATTCTATCTTCCAGCATAT-
3′) into the XbaI–BamHI sites of pUG23. In this construct, GFP is
fused to CDC9 after residue 70. The entire inserts of both plasmids
were sequenced by automated sequencing. 
Subcellular fractionation
Yeast mitochondria and a post-mitochondrial supernatant were pre-
pared as described previously [24]. Yeast nuclei were prepared as
follows. Cells were grown in YPD to mid-exponential phase, harvested
by centrifugation and converted into sphaeroplasts [24], which were
pelleted, washed twice with 1.2 M sorbitol, 20 mM potassium phos-
phate pH 6.5 and resuspended in cold 18% Ficoll 400 (w/v), 20 mM
potassium phosphate pH 6.5, 0.5 mM MgCl2. Sphaeroplasts were
then homogenised by two strokes with a Dounce homogeniser on ice.
An equal volume of 2.4 M sorbitol, 20 mM potassium phosphate
pH 6.5, 0.5 mM MgCl2 was added and the homogenate was spun at
1000 × g for 10 min at 4ºC to remove unbroken cells and cell debris.
The supernatant was transferred to a fresh tube and nuclei were pel-
leted by centrifugation at 12000 × g for 25 min at 4ºC. The pellet was
resuspended in a small volume of 1.2 M sorbitol, 20 mM potassium
phosphate pH 6.5, 0.5 mM MgCl2 and layered on top of a three-step
glycerol gradient as described by Kalinich and Douglas [34]. The
nuclear fraction was then further purified by centrifugation on a
sucrose gradient as described by Hurt et al. [25]. Proteinase K treat-
ment of isolated mitochondria and nuclei was carried out by adding an
equal volume of 500 µg/ml proteinase K in 0.6 M mannitol, 10 mM
Tris-HCl pH 7.4. Triton X-100 was added to a final concentration of
0.5%. After incubation at 0ºC for 30 min, proteins were TCA precipi-
tated. SDS-containing sample buffer was added and the samples were
immediately heated to 95ºC for 4 min and analysed by SDS–PAGE as
described below.
Western blotting
Methods for the preparation of whole cell extracts and for SDS–PAGE
and immunoblotting were as described previously [33]. Antiserum
directed against yeast Hsp60 was used at 1:10,000 dilution
(K. Tokatlidis, personal communication), anti-Npl3 antiserum at
1:3000 dilution (A.H. Corbett, personal communication), anti-GFP
antiserum at 1:1000 dilution and anti-HA monoclonal antibody
(12CA5/Boehringer Mannheim) at 1:1000 dilution. Secondary HRP-
conjugated anti-rabbit antibody (Sigma) and HRP-conjugated anti-
mouse antibody (DAKO) were both used at a 1:10,000 dilution before
detection with Renaissance ECL (NEN).
Site-directed mutagenesis of CDC9
A 1136 bp PstI–XhoII fragment from pR12ScLig2 [35] containing the
promoter region and part of the CDC9 ORF was cloned into the
PstI–BamHI sites of YIp351 [36]. The resulting plasmid, pMW185 was
subjected to site-directed mutagenesis performed with Quickchange
site-directed mutagenesis kit (Stratagene) according to the manufactur-
er’s instructions. The first ATG of the CDC9 ORF in pMW185 was
changed to TAG (stop codon) using primers D (5′-CATTGTTCATCAAT-
TACTAGCGCAGATTACTGACC-3′) and E (5′-GGTCAGTAATCT-
GCGCTAGTAATTGATGAACAATG-3′) to produce pMW186. In
pMW190, the second ATG of the CDC9 ORF in pMW185 was
changed to GCG (Ala) with primers F (5′-CCTTGAAATCAAGATTGC-
CATTATTGGCGTCATCCTCATTACCTTCC-3′) and G (5′-GGAAG-
GTAATGAGGATGACGCCAATAATGGCAATCTTGATTTCAAGG-3′).
The inserts of pMW186 and pMW190 were sequenced to verify the
changes of the DNA sequence. Subsequently, the two mutant plasmids
and a wild-type control (pMW185) were linearised with NdeI and trans-
formed into MDY26 (CDC9/CDC9–HA) selecting for leucine auxotro-
phy. All integrations were confirmed by PCR of genomic DNA using
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primers J (5′-CCGGATCTATGCGGTGTGAAATAC-3′) and K (5′-
ATGCACCTGAGCCCTTTCACCATC-3′). The diploid strains contain-
ing the integrated constructs were named: MWY21
(pMW185/wild-type), MWY32 (pMW186/AUG1→UAG) and MWY51
(pMW190/AUG2→GCG). All three strains were transformed with
pR12ScLig2 selecting for leucine/uracil auxotrophy and tetrad analysis
revealed a 2:2 segregation of the leucine auxotrophy, suggesting a
single integration event in each of the strains MWY21, MWY32 and
MWY51. Finally, the effects of the individual ATG mutants were
assessed by tetrad analysis of the three diploid strains. Mutagenesis of
the second and third ATG in pMW181 (CDC9–GFP, described
above) was performed in two steps: the third ATG of CDC9 in
pMW181 was changed to GCG with primers H (5′-GGCTA-
GATTCTTCACTTCCGCGAAAAATAAGCCAACAGAAGG-3′) and I
(5′-CCTTCTGTTGGCTTATTTTTCGCGGAAGTGAAGAATCTAGCC-
3′), resulting in pMW197 in which the second ATG was changed to
GCG with primers F and G (pMW198). The correct changes were ver-
ified by DNA sequencing.
Immunofluorescence microscopy
Cells were grown to mid-logarithmic phase in minimal media selecting
for the presence of plasmid, as appropriate, and fixed by addition of
formaldehyde to a final concentration of 4.4% and subsequently
treated as described [37]. Cells were incubated for 60 min with
1:1000 dilution of anti-Hsp60 antisera in PBS + 1 mg/ml BSA. Cy3-
coupled anti-rabbit secondary antibody was used at 1:1000 dilution for
60 min. Hsp60 staining was visualised by immunofluorescence
microscopy using a Leica TCS NT confocal microscope and associ-
ated software supplied by the manufacturer. Simultaneous recording of
GFP signal was performed and 25 individual sections throughout each
sample were integrated. 
Epitope tagging with transposon
As a target for mTn3-3xHA/lacZ transposon insertion, a 1886 bp
BglII–XbaI fragment containing the amino-terminal part of CDC9 was
cloned from pR12ScLig2 into the BamHI–XbaI sites of the vector
pHSS6. This plasmid (pHSS6-CDC9) was subjected to transposon
mutagenesis as described [23]. One haploid viable strain, MDY26,
expressing a functional CDC9–HA was chosen for further analysis.
Genomic DNA from MDY26 was amplified by PCR with primers
L (5′-CACCTTAACGCGAAAACGCGTGAAAGTG-3′) and M (5′-
TTTGACCCACAAAGGTGGGAAAAGTGCC-3′) and sequenced to
determine the position of the 279 bp 3 × HA insertion.
Supplementary material
A supplementary figure showing Cdc9–GFP localisation in intact yeast
cells is available at http://current-biology.com/supmat/supmatin.htm.
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S1Supplementary material
Figure S1
Cdc9–GFP localisation in intact yeast cells. (a) Fluorescence
microscopy of wild-type cells expressing the Cdc9–GFP fusion protein
from pMW181 (AUG1–4) revealed a punctuate/tubular pattern
compared with the vector control (pUG23). (b) Cdc9–GFP staining
overlapped substantially with mitochondrial DNA in DAPI-stained cells.
Cells were fixed and stained as described in the Materials and
methods section. For DAPI staining, fixed cells were washed twice
with PBS and then stained with 1 µg/ml DAPI for 5 min. Stained cells
were then washed twice with PBS and then mounted in 1 mg/ml
p-phenylenediamine in 90% glycerol before examination on a Zeiss
Axiophot fluorescence microscope.
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